You are here

Share:

Search Technologies

Showing 1-20 of 354 results found

Autophagy Modulators For Use in Treating Cancer

Investigators from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have identified five autophagy-inhibiting compounds (WX8 family) through a high-throughput screening. The NICHD seeks licensees and/or co-development partners for methods to treat cancer by administering these autophagy-inhibiting compounds.

Monoclonal Antibody Fragments for Targeting Therapeutics to Growth Plate Cartilage

In collaboration with the National Cancer Institute (NCI), researchers at The Eunice Kennedy Shriver National Institute on Child Health and Human Development (NICHD) have discovered monoclonal antibodies that bind to matrilin-3, a protein specifically expressed in cartilage tissue, that could be used for treating or inhibiting growth plate disorders, such as a skeletal dysplasia or short stature. The monoclonal antibodies can also be used to target therapeutic agents, such as those for anti-arthritis, to cartilage tissue. NICHD seeks statements of capability or interest from parties interested in collaborative research to co-develop, evaluate, and/or commercialize treatment of skeletal disorders using targeting antibodies.

T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy

Researchers at the National Institutes of Health have identified a collection of TCRs that exclusively recognize the common hotspot driver mutations in KRAS antigen, expressed by a variety of epithelial cancers, including pancreatic, colorectal and lung cancer. The mutated KRAS variants are recognized by the TCRs in the context of specific Class I/Class II HLA alleles. These TCRs can be used for a variety of experimental therapeutic, diagnostic and research applications.

Use of the TP5 Peptide for the Treatment of Cancer

Increased cyclin-dependent kinase 5 (CDK5) activity has recently emerged as a contributor to cancer progression. Researchers at the National Cancer Institute (NCI) and at the National Institute of Neurological Disorders and Stroke (NINDS) have shown that TP5, a small peptide inhibitor of CDK5 modified to facilitate passage through the blood brain barrier (BBB), has potential therapeutic benefit in glioblastoma (GBM) and colorectal carcinoma (CRC). NCI is seeking parties interested in co-developing and/or licensing TP5 for its use in the treatment of cancers with aberrant CDK5 expression as a mono-therapy or in an adjuvant setting with current standard-of-care.

Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment

Researchers at the National Cancer Institute (NCI) have developed aryl hydantoin heterocycles that target the androgen receptor (AR). NCI seeks research co-development partners and/or licensees to develop these compounds as therapeutics for prostate cancer. As these compounds consist of both AR agonists and antagonists, they may also be effective therapeutics for androgen dysfunctional disorders, such as androgen deficiency disorders or hyperandrogenism.

Mouse Embryo Culture Chamber and Imaging System and Methods of Use

Scientists at the National Eye Institute (NEI) have developed an embryo culture chamber, which can be used to culture and image embryos. The chamber allows for the continuous imaging of the embryo for the culture period. NEI seeks research collaborations and/or licensees for the development of this culture and imaging chamber for murine embryos.

Mitotic Figures Electronic Counting Application for Surgical Pathology

National Cancer Institute (NCI) researchers have developed a novel software tool for uniform recording of Mitotic Figure (MF) counts via conventional and/or digital microscopy. With this technology, diagnostic centers can standardize electronic recording, summation, and transcription of clinical data during surgical pathology examination. NCI seeks licensing partners to further develop this application for use in diagnosis and detection of malignant cancers.

Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images

The National Cancer Institute (NCI) seeks research, co-development, or licensing partners for software that uses computational approaches in cancer diagnosis. NCI researchers have recently developed a computational approach for detecting, quantifying, and mapping Mitotic Hotspots in whole slide images of tumor tissue. This technology has demonstrated high reproducibility that is unaffected by diagnostic skill or fatigue, allowing standardization of tumor cell proliferation assessment across institutions.

Reporter Plasmid to Identify Cancer Stem Cells

The National Cancer Institute’s Laboratory of Cancer Biology and Genetics seeks partners to co-develop lentiviral plasmids, a research tool for visualizing and purifying cancer stem cells.

Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy

There remains a need for effective immunotherapies to treat solid tumors as well as hematological malignancies. Researchers at the National Cancer Institute (NCI) have designed novel chimeric adaptor proteins (CAPs) consisting of signaling molecules downstream of the T cell receptor (TCR) for use in T cell-mediated immunotherapy. NCI is seeking parties interested in licensing and/or co-developing CAPs that can be used in immunotherapy for treating cancer, including both hematological and solid malignancies.

Nanoparticle delivery of lung cancer therapeutic

The National Cancer Institute seeks parties interested in licensing an improved treatment for non-small cell lung cancer based on inhalation of nano- and microparticle therapeutics.

Pages